Endologix, Inc. (NASDAQ:ELGX) Expected to Post Earnings of -$0.63 Per Share

Share on StockTwits

Wall Street brokerages expect that Endologix, Inc. (NASDAQ:ELGX) will report earnings per share of ($0.63) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Endologix’s earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.57). Endologix posted earnings per share of ($1.50) in the same quarter last year, which suggests a positive year over year growth rate of 58%. The firm is scheduled to report its next quarterly earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Endologix will report full year earnings of ($2.69) per share for the current year, with EPS estimates ranging from ($3.02) to ($2.36). For the next year, analysts expect that the business will report earnings of ($2.51) per share, with EPS estimates ranging from ($4.36) to ($1.71). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Endologix.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.43. Endologix had a negative net margin of 60.32% and a negative return on equity of 154.23%. The business had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million.

A number of equities analysts have commented on ELGX shares. Royal Bank of Canada set a $7.00 price objective on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, August 9th. ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Endologix from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. Endologix currently has an average rating of “Hold” and a consensus target price of $20.25.

Hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP boosted its stake in shares of Endologix by 49.0% during the 4th quarter. Two Sigma Investments LP now owns 804,212 shares of the medical instruments supplier’s stock worth $576,000 after purchasing an additional 264,453 shares during the period. BlackRock Inc. boosted its stake in shares of Endologix by 8.9% during the 4th quarter. BlackRock Inc. now owns 6,208,597 shares of the medical instruments supplier’s stock worth $4,446,000 after purchasing an additional 509,493 shares during the period. Northern Trust Corp boosted its stake in shares of Endologix by 15.9% during the 4th quarter. Northern Trust Corp now owns 1,215,671 shares of the medical instruments supplier’s stock worth $871,000 after purchasing an additional 166,409 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Endologix by 79.5% during the 4th quarter. Two Sigma Advisers LP now owns 249,082 shares of the medical instruments supplier’s stock worth $178,000 after purchasing an additional 110,300 shares during the period. Finally, Citigroup Inc. boosted its stake in shares of Endologix by 279.2% during the 4th quarter. Citigroup Inc. now owns 51,448 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 37,882 shares during the period. 48.44% of the stock is owned by hedge funds and other institutional investors.

Shares of NASDAQ:ELGX traded down $0.30 on Thursday, reaching $6.11. The company’s stock had a trading volume of 218,945 shares, compared to its average volume of 240,310. Endologix has a 52-week low of $5.20 and a 52-week high of $26.50. The company has a market cap of $113.78 million, a P/E ratio of -0.85 and a beta of 0.37. The business has a 50-day moving average price of $6.81. The company has a current ratio of 1.58, a quick ratio of 0.90 and a debt-to-equity ratio of 11.12.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Featured Article: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.